Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Sudden Cardiac Death | Research

Complement component 7 is associated with total- and cardiac death in chest-pain patients with suspected acute coronary syndrome

Authors: Reidun Aarsetøy, Thor Ueland, Pål Aukrust, Annika E. Michelsen, Ricardo Leon de la Fuente, Heidi Grundt, Harry Staines, Ottar Nygaard, Dennis W. T. Nilsen

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Background

Complement activation has been associated with atherosclerosis, atherosclerotic plaque destabilization and increased risk of cardiovascular events. Complement component 7 (CC7) binds to the C5bC6 complex which is part of the terminal complement complex (TCC/C5b-9). High-sensitivity C-reactive protein (hsCRP) is a sensitive marker of systemic inflammation and may reflect the increased inflammatory state associated with cardiovascular disease.

Aim

To evaluate the associations between CC7 and total- and cardiac mortality in patients hospitalized with chest-pain of suspected coronary origin, and whether combining CC7 with hsCRP adds prognostic information.

Methods

Baseline levels of CC7 were related to 60-months survival in a prospective, observational study of 982 patients hospitalized with a suspected acute coronary syndrome (ACS) at 9 hospitals in Salta, Argentina. A cox regression model, adjusting for conventional cardiovascular risk factors, was fitted with all-cause mortality, cardiac death and sudden cardiac death (SCD) as the dependent variables. A similar Norwegian population of 871 patients was applied to test the reproducibility of results in relation to total death.

Results

At follow-up, 173 patients (17.7%) in the Argentinean cohort had died, of these 92 (9.4%) were classified as cardiac death and 59 (6.0%) as SCD. In the Norwegian population, a total of 254 patients (30%) died. In multivariable analysis, CC7 was significantly associated with 60-months all-cause mortality [hazard ratio (HR) 1.26 (95% confidence interval (CI), 1.07–1.47) and cardiac death [HR 1.28 (95% CI 1.02–1.60)], but not with SCD. CC7 was only weakly correlated with hsCRP (r = 0.10, p = 0.002), and there was no statistically significant interaction between the two biomarkers in relation to outcome. The significant association of CC7 with total death was reproduced in the Norwegian population.

Conclusions

CC7 was significantly associated with all-cause mortality and cardiac death at 60-months follow-up in chest-pain patients with suspected ACS.

Clinical trial registration

ClinicalTrials.gov Identifier: NCT01377402, NCT00521976.
Appendix
Available only for authorised users
Literature
1.
go back to reference Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.CrossRef Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.CrossRef
2.
go back to reference Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315:2532–41.CrossRef Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315:2532–41.CrossRef
3.
go back to reference Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51:45–60.CrossRef Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51:45–60.CrossRef
4.
go back to reference Hovland A, Jonasson L, Garred P, et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241:480–94.CrossRef Hovland A, Jonasson L, Garred P, et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241:480–94.CrossRef
5.
go back to reference Lappegård KT, Garred P, Jonasson L, et al. A vital role for complement in heart disease. Mol Immunol. 2014;61:126–34.CrossRef Lappegård KT, Garred P, Jonasson L, et al. A vital role for complement in heart disease. Mol Immunol. 2014;61:126–34.CrossRef
6.
go back to reference Vlaicu SI, Tatomir A, Rus V, et al. The role of complement activation in atherogenesis: the first 40 years. Immunol Res. 2016;64:1–13.CrossRef Vlaicu SI, Tatomir A, Rus V, et al. The role of complement activation in atherogenesis: the first 40 years. Immunol Res. 2016;64:1–13.CrossRef
7.
go back to reference Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35–50.CrossRef Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35–50.CrossRef
8.
go back to reference Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9:802–11.CrossRef Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9:802–11.CrossRef
9.
go back to reference Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1214–9.CrossRef Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1214–9.CrossRef
10.
go back to reference Yan W, Che L, Jiang J, et al. Depletion of complement system immunity in patients with myocardial infarction. Mol Med Rep. 2016;14:5350–6.CrossRef Yan W, Che L, Jiang J, et al. Depletion of complement system immunity in patients with myocardial infarction. Mol Med Rep. 2016;14:5350–6.CrossRef
11.
go back to reference Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156–63.CrossRef Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156–63.CrossRef
12.
go back to reference Hoffmeister HM, Ehlers R, Büttcher E, et al. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2002;89:909–12.CrossRef Hoffmeister HM, Ehlers R, Büttcher E, et al. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2002;89:909–12.CrossRef
13.
go back to reference Ilczuk T, Wasiutynski A, Wilczek E, Gornicka B. The study of the protein complement in myocardial infarction. Immunol Lett. 2014;162:262–8.CrossRef Ilczuk T, Wasiutynski A, Wilczek E, Gornicka B. The study of the protein complement in myocardial infarction. Immunol Lett. 2014;162:262–8.CrossRef
14.
go back to reference Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor, more than an epiphenomenon? Circulation. 1999;100:96–102.CrossRef Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor, more than an epiphenomenon? Circulation. 1999;100:96–102.CrossRef
15.
go back to reference Leóndela Fuente RL, Naesgaard PA, Nilsen ST, et al. B-type natriuretic peptide and high-sensitive C-reactive protein predict 2-year all-cause mortality in chest pain patients: a prospective observational study from Salta, Argentina. BMC Cardiovasc Disord. 2011;11:57. https://doi.org/10.1186/1471-2261-11-57.CrossRef Leóndela Fuente RL, Naesgaard PA, Nilsen ST, et al. B-type natriuretic peptide and high-sensitive C-reactive protein predict 2-year all-cause mortality in chest pain patients: a prospective observational study from Salta, Argentina. BMC Cardiovasc Disord. 2011;11:57. https://​doi.​org/​10.​1186/​1471-2261-11-57.CrossRef
16.
go back to reference Lindberg S, Pedersen SH, Mogelvang R, et al. Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am Heart J. 2012;164:786–92.CrossRef Lindberg S, Pedersen SH, Mogelvang R, et al. Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am Heart J. 2012;164:786–92.CrossRef
17.
go back to reference Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type II diabetes and myocardial infarction. Diabetes Care. 2012;35:911–7.CrossRef Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type II diabetes and myocardial infarction. Diabetes Care. 2012;35:911–7.CrossRef
18.
go back to reference Palikhe A, Sinisalo J, Seppänen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;99:890–5.CrossRef Palikhe A, Sinisalo J, Seppänen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;99:890–5.CrossRef
19.
go back to reference Széplaki G, Prohászka Z, Duba J, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Aterosclerosis. 2004;177:383–9.CrossRef Széplaki G, Prohászka Z, Duba J, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Aterosclerosis. 2004;177:383–9.CrossRef
20.
go back to reference Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357–64.CrossRef Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357–64.CrossRef
21.
go back to reference Speidl WS, Exner M, Amighi J, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J. 2005;26:2294–9.CrossRef Speidl WS, Exner M, Amighi J, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J. 2005;26:2294–9.CrossRef
22.
go back to reference Galvani M, Ottani F, Oltrona L, et al. N-terminal Pro-Brain Natriuretic Peptide on admission has prognostic value across the whole spectrum of acute coronary syndrome. Circulation. 2004;110:128–34.CrossRef Galvani M, Ottani F, Oltrona L, et al. N-terminal Pro-Brain Natriuretic Peptide on admission has prognostic value across the whole spectrum of acute coronary syndrome. Circulation. 2004;110:128–34.CrossRef
23.
go back to reference Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315.CrossRef Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315.CrossRef
24.
go back to reference Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JCM. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis. 2007;195:e195-202.CrossRef Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JCM. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis. 2007;195:e195-202.CrossRef
25.
go back to reference Berk BC, Weintraub WS, Alexander W. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168–72.CrossRef Berk BC, Weintraub WS, Alexander W. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168–72.CrossRef
26.
go back to reference Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–6.CrossRef Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–6.CrossRef
27.
go back to reference Ridker PM. A test in context; high-sensitivity c-reactive protein. J Am Coll Cardiol. 2016;67:712–23.CrossRef Ridker PM. A test in context; high-sensitivity c-reactive protein. J Am Coll Cardiol. 2016;67:712–23.CrossRef
28.
go back to reference The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.CrossRef The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.CrossRef
29.
go back to reference Diederichsen MZ, Diederichsen SZ, Mickley H, et al. Prognostic value of suPAR and hs-CRP on cardiovascular disease. Atherosclerosis. 2018;16:245–51.CrossRef Diederichsen MZ, Diederichsen SZ, Mickley H, et al. Prognostic value of suPAR and hs-CRP on cardiovascular disease. Atherosclerosis. 2018;16:245–51.CrossRef
31.
go back to reference Mjelva ØR, Pönitz V, Brügger-Andersen T, Grundt H, Staines H, Nilsen DWT. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. Eur J Prev Cardiol. 2016;23:1130–40.CrossRef Mjelva ØR, Pönitz V, Brügger-Andersen T, Grundt H, Staines H, Nilsen DWT. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. Eur J Prev Cardiol. 2016;23:1130–40.CrossRef
Metadata
Title
Complement component 7 is associated with total- and cardiac death in chest-pain patients with suspected acute coronary syndrome
Authors
Reidun Aarsetøy
Thor Ueland
Pål Aukrust
Annika E. Michelsen
Ricardo Leon de la Fuente
Heidi Grundt
Harry Staines
Ottar Nygaard
Dennis W. T. Nilsen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-02306-w

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue